Latona to acquire patent rights and orphan status for arthritis drug

Latona has entered into a licensing agreement to acquire the patent rights to Oralgam with Research Corporation Technologies. Under the terms of this agreement, Latona will acquire the exclusive worldwide rights to Oralgam for the treatment of adult rheumatoid arthritis and the treatment of auto-immune induced hearing loss.

Latona has also entered into a purchase and sale agreement to acquire the orphan drug status, clinical data set and trademark to Oralgam with Protein Therapeutics. Under the terms of this agreement Latona will acquire the orphan drug status to Oralgam for the treatment of juvenile rheumatoid arthritis, gastrointestinal dysfunction in autism and dermatomyostis.